{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:44:51Z","timestamp":1746326691051},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We report a case of progressive Granulomatosis with Polyangiitis (Wegener\u2019s Granulomatosis) with life-threatening complications of both the underlying disease and induction immunosuppressive therapy. Here, for the first time, cyclophosphamide toxicity and severe opportunistic infections including <jats:italic>pneumocystis jirovecii<\/jats:italic>- pneumonia were found in one case in a close temporal relationship.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 34-year-old male patient of Caucasian ethnicity presented with acute renal failure necessitating hemodialysis treatment due to Granulomatosis with Polyangiitis (Wegener\u2019s Granulomatosis). Kidney disease progressed to end-stage renal disease shortly after first diagnosis. After the 2<jats:sup>nd<\/jats:sup> bolus of cyclophosphamide shortly, induction immunosuppression (glucocorticoid\/cyclophosphamide) was interrupted for repeat infections and resumed 5 years later. By that time, the lungs developed large pulmonary cavernae most likely due to smoldering granuloma indicative for the failed goal of disease remission. Therefore, induction immunosuppression was resumed. Following two monthly boli of cyclophosphamide, the patient developed pericardial effusion and, consecutively, atrioventricular blockade most likely due to cyclophosphamide. After recovery, the patient was discharged without cotrimoxacole. 10 weeks after the last cyclophosphamide bolus and 6 weeks after cessation of cotrimoxacole, the patient was readmitted to the intensive-care unit with Pneumocystis jirovecii pneumonia, and died 6 months later or 74 months after first diagnosis of Granulomatosis with Polyangiitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This case illustrates both the need for adequate immunosuppressive therapy to reach disease remission and the limitations thereof in terms of complications including cardiotoxicity of cyclophosphamide and <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia. In line with current recommendations, the present case strongly encourages <jats:italic>pneumocystis jirovecii<\/jats:italic>- pneumonia chemoprophylaxis for at least 6 months following induction therapy in Granulomatosis with Polyangiitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-15-28","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T12:03:22Z","timestamp":1391515402000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis"],"prefix":"10.1186","volume":"15","author":[{"given":"Elena","family":"Ernst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Girndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer U","family":"Pliquett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"733_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10792-007-9109-y","volume":"28","author":"M Ahmed","year":"2008","unstructured":"Ahmed M, Niffenegger JH, Jakobiec FA, Ben-Arie-Weintrob Y, Gion N, Androudi S, et al: Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. Int Ophthalmol. 2008, 28: 35-46. 10.1007\/s10792-007-9109-y.","journal-title":"Int Ophthalmol"},{"key":"733_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMp048338","volume":"352","author":"PA Bacon","year":"2005","unstructured":"Bacon PA: The spectrum of Wegener\u2019s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056\/NEJMp048338.","journal-title":"N Engl J Med"},{"key":"733_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/03009740310004063","volume":"33","author":"NO Ghaussy","year":"2004","unstructured":"Ghaussy NO, Du Clos TW, Ashley PA: Limited Wegener\u2019s granulomatosis presenting with complete heart block. Scand J Rheumatol. 2004, 33: 115-118. 10.1080\/03009740310004063.","journal-title":"Scand J Rheumatol"},{"key":"733_CR4","first-page":"445","volume":"19","author":"Q Qian","year":"2010","unstructured":"Qian Q, Cornell L, Chandan V, Hartman R, Caples S: Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. J Gastrointestin Liver Dis. 2010, 19: 445-447.","journal-title":"J Gastrointestin Liver Dis"},{"key":"733_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.revmed.2009.06.007","volume":"31","author":"G Sarlon","year":"2010","unstructured":"Sarlon G, Durant C, Grandgeorge Y, Bernit E, Veit V, Hamidou M, et al: Cardiac involvement in Wegener\u2019s granulomatosis: report of four cases and review of the literature. Rev Med Interne. 2010, 31: 135-139. 10.1016\/j.revmed.2009.06.007.","journal-title":"Rev Med Interne"},{"key":"733_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMp048338","volume":"352","author":"PA Bacon","year":"2005","unstructured":"Bacon PA: The spectrum of Wegener\u2019s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056\/NEJMp048338.","journal-title":"N Engl J Med"},{"key":"733_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136\/ard.2008.088096.","journal-title":"Ann Rheum Dis"},{"key":"733_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007, 82: 1052-1059. 10.4065\/82.9.1052.","journal-title":"Mayo Clin Proc"},{"key":"733_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, De Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056\/NEJM199607043350103.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"733_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186\/2047-783X-14-S4-265.","journal-title":"Eur J Med Res"},{"key":"733_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.090843","volume":"37","author":"D Cettomai","year":"2010","unstructured":"Cettomai D, Gelber AC, Christopher-stine L: A survey of Rheumatologists\u0393\u00c7\u00d6 practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010, 37: 792-799. 10.3899\/jrheum.090843.","journal-title":"J Rheumatol"},{"key":"733_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2310\/7750.2009.09010","volume":"13","author":"P Grewal","year":"2009","unstructured":"Grewal P, Brassard A: Fact or fiction: does the non-HIV\/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg. 2009, 13: 308-312.","journal-title":"J Cutan Med Surg"},{"key":"733_CR13","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"R Mehta","year":"2007","unstructured":"Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D, et al: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11: R31-10.1186\/cc5713.","journal-title":"Crit Care"},{"key":"733_CR14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18: 2180-2188. 10.1681\/ASN.2007010090.","journal-title":"J Am Soc Nephrol"},{"key":"733_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3899\/jrheum.091426","volume":"37","author":"LK Stamp","year":"2010","unstructured":"Stamp LK, Hurst M: Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?. J Rheumatol. 2010, 37: 686-688. 10.3899\/jrheum.091426.","journal-title":"J Rheumatol"},{"key":"733_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136\/ard.2008.088096.","journal-title":"Ann Rheum Dis"},{"key":"733_CR17","first-page":"S1","volume":"9","author":"S Issue","year":"2009","unstructured":"Issue S: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009, 9: S1-S155.","journal-title":"Am J Transplant"},{"issue":"Suppl 4","key":"733_CR18","first-page":"1","volume":"17","author":"EBPG Expert Group on Renal Transplantation","year":"2002","unstructured":"EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant. 2002, 17 (Suppl 4): 1-67.","journal-title":"Nephrol Dial Transplant"},{"key":"733_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/ard.54.12.991","volume":"54","author":"B Godeau","year":"1995","unstructured":"Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du Huong LT, et al: Factors associated with pneumocystis carinii pneumonia in Wegener\u2019s granulomatosis. Ann Rheum Dis. 1995, 54: 991-994. 10.1136\/ard.54.12.991.","journal-title":"Ann Rheum Dis"},{"key":"733_CR20","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1093\/ndt\/14.12.2807","volume":"14","author":"M Girndt","year":"1999","unstructured":"Girndt M, Sester U, Sester M, Kaul H, K+\u00c2hler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999, 14: 2807-2810. 10.1093\/ndt\/14.12.2807.","journal-title":"Nephrol Dial Transplant"},{"key":"733_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/ndt\/13.7.1713","volume":"13","author":"M Haubitz","year":"1998","unstructured":"Haubitz M, Koch KM, Brunkhorst R: Survival and vasculitis activity in patients with end-stage renal disease due to Wegener\u2019s granulomatosis. Nephrol Dial Transplant. 1998, 13: 1713-1718. 10.1093\/ndt\/13.7.1713.","journal-title":"Nephrol Dial Transplant"},{"key":"733_CR22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986, 68: 1114-1118.","journal-title":"Blood"},{"key":"733_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jjcc.2009.01.006","volume":"54","author":"M Katayama","year":"2009","unstructured":"Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, et al: Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009, 54: 330-334. 10.1016\/j.jjcc.2009.01.006.","journal-title":"J Cardiol"},{"key":"733_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.breast.2004.02.007","volume":"13","author":"A Tiersten","year":"2004","unstructured":"Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, et al: Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast. 2004, 13: 341-346. 10.1016\/j.breast.2004.02.007.","journal-title":"Breast"},{"key":"733_CR25","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","volume":"61","author":"M Haubitz","year":"2002","unstructured":"Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002, 61: 1495-1501. 10.1046\/j.1523-1755.2002.00279.x.","journal-title":"Kidney Int"},{"key":"733_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, PE DJ, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056\/NEJM199607043350103.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"733_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186\/2047-783X-14-S4-265.","journal-title":"Eur J Med Res"},{"key":"733_CR28","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/rheumatology\/ken373","volume":"47","author":"U Erdbruegger","year":"2008","unstructured":"Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, et al: Diagnostic role of endothelial microparticles in vasculitis. Rheumatology. 2008, 47: 1820-1825. 10.1093\/rheumatology\/ken373.","journal-title":"Rheumatology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-15-28\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:03:08Z","timestamp":1630551788000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-15-28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-15-28","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]},"assertion":[{"value":"17 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"28"}}